Results 291 to 300 of about 136,428 (330)
Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction. [PDF]
Scalia IG +9 more
europepmc +1 more source
Glucagon-like peptide-1 analogs reduce alcohol intake
Maurice O'Farrell +2 more
openaire +2 more sources
Abstract Aims Obesity is a growing global health crisis; pharmacotherapies such as tirzepatide combined with multidisciplinary lifestyle support have shown promise but real‐world evidence in digital weight‐loss services (DWLSs) is limited. This retrospective study evaluated 6‐ and 12‐month weight loss, adherence and predictors of outcomes in an ...
Louis Talay +3 more
wiley +1 more source
Diabetic kidney disease, biomarkers, and finerenone
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley +1 more source
Pharmacological Privilege: How Glucagon-Like Peptide-1 (GLP-1) Medications are Widening Health Inequalities. [PDF]
Brennan-Davies AH, Lakey S.
europepmc +1 more source
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders. [PDF]
De Giorgi R +4 more
europepmc +1 more source
Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea. [PDF]
D'Annibale DA +3 more
europepmc +1 more source
Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies. [PDF]
Myers WK, Heath G, Rohrer B.
europepmc +1 more source

